Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amphastar Pharmaceuticals, Inc. - Common Stock
(NQ:
AMPH
)
27.12
+0.31 (+1.16%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amphastar Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Amphastar Director Sells 16,679 Shares for $441,800
↗
December 23, 2025
Amphastar is down big in 2025, but recently announced positive FDA-related news.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Healthcare Stocks with Questionable Fundamentals
December 15, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...
Via
StockStory
Topics
Stocks
Amphastar Announces FDA Approval for Teriparatide Injection
December 15, 2025
Via
ACCESS Newswire
2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges
December 11, 2025
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...
Via
StockStory
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
December 08, 2025
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...
Via
StockStory
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why
December 03, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential...
Via
StockStory
Topics
Economy
Amphastar (AMPH) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Amphastar (AMPH) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
November 24, 2025
Via
ACCESS Newswire
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
November 21, 2025
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...
Via
StockStory
Topics
Economy
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
November 19, 2025
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Small-Cap Stocks with Questionable Fundamentals
November 17, 2025
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...
Via
StockStory
5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call
November 13, 2025
Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was...
Via
StockStory
Topics
Earnings
Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)
November 12, 2025
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
November 12, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
November 12, 2025
Via
ACCESS Newswire
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
November 11, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today
November 10, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures
November 10, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP...
Via
StockStory
Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today
November 07, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst...
Via
StockStory
Topics
Artificial Intelligence
Economy
Government
The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts
↗
November 07, 2025
Via
Benzinga
Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers
November 06, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
November 06, 2025
Via
ACCESS Newswire
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
November 04, 2025
Via
StockStory
1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm
October 30, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
Topics
Economy
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
October 27, 2025
Via
ACCESS Newswire
2 Reasons AMPH is Risky and 1 Stock to Buy Instead
October 27, 2025
Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period.
Via
StockStory
Topics
Economy
Government
Stocks
Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews
↗
October 22, 2025
Via
Benzinga
Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know
October 10, 2025
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Via
StockStory
Topics
Economy
Government
World Trade
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
↗
October 09, 2025
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.
Via
Benzinga
Topics
Government
World Trade
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.